% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • scistats scistats Jan 25, 2013 12:23 PM Flag

    Revenues from the distribution of Biosurgery products: Three months ended Dec 31, 2012 = $1,500,000 (my best guess)

    Revenues from the distribution of Biosurgery products:

    Three months ended December 31, 2012 Gross profit $1,500,000 (my best guess)
    Three months ended September 30, 2012 Gross profit $1,400,000
    Three months ended June 30, 2012 Gross profit $1,100,0000
    Three months ended March 31, 2012 Gross profit $750,000
    Three months ended December 31, 2011 Gross profit $443,000
    Three months ended September 30, 2011 Gross profit $192,000
    Three months ended June 30, 2011 Gross profit of $75,000
    Three months ended March 31, 2011 Gross profit of $22,000
    Three months ended December 31, 2010 Gross profit of $56,000
    Three months ended September 30, 2010 Gross profit of $65,000

    "We commenced limited sales of our Biosurgery products during the third quarter of 2010," "During the three months ended December 31, 2012, we recognized $2.0 million of product revenues from the distribution of Grafix and Ovation and realized gross profit of $1.5 million." (my best guess)

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Place your bet Daniel.

      Sentiment: Strong Buy

    • Sci guy, this time you are way low. Let's try $3500,000.00 Doctors love their patiens and need to score five stars on their patients surveys so they can attract more patients and build their reputation and business. effective medicine will not be kept in the dark for very much longer.

      We all know the power of Osiris, ovation, grafix, cartiform and many many many more product to come out of the lab.

      Now is not the time to be playing the market with shares or options, NOW is the time to be accumulating bargain shares.

      History repeats itself. six moths from now $35 plus. Take it to the bank, or should it be take the cash out of the bank and buy, buy, BUY OSIRIS, you will not regret it.

      Sentiment: Strong Buy

      • 2 Replies to ativaloc
      • Where is our FRIEND the big short Bonk the dork that the share price will not be above $6 and where is that so called analyst that recomended to his clients to short OSIR at $5

        These same dodo's are professionals who made the wrong bet on the right stoch who have yet to cover their massive naked short positions.

        Viva La Dork I will not sleep until he posts

        May the stem cells be with you

        PS wielly smilly with no teeth will not last another month(smile and say good by James) to think he is a swing trader that boast his great calls. See ya all at $167 by December 2013 Go back and llisten and watch the CC see the little girl, What Grafix does on the outside Ovation does on the inside.

        Sentiment: Strong Buy

      • I share your enthusiasm, but agree with Oz that the ramp up probably started in January with the reimbursement codes. Q4 2012 will be somewhat lackluster as Osiris just now cut the Grafix instructional video and is marching forward toward earnest deployment of a marketing campaign that will make Pete green in the face.

        I feel pretty sure about the $1.5 million gross profit for biosurgery, which is not a bad way to start. The Prochymal AMI results will tell the tale. Swissmedic needs to make a decision. And for some reason, Angiotech is recovering from BK and might just be the perfect partner. Their Quill distribution aligns well with Grafix, Ovation, and Cartiform.

        They would be enthusiastic to move.

        Read this:
        Following the acquisition of American Medical Instruments Holdings, Inc. in 2006, Angiotech expanded beyond its strong R&D capabilities to encompass the manufacturing and marketing of a wide range of single use, specialty medical devices, focused on interventional, surgical and OEM markets. Angiotech is currently working to develop a portfolio of next-generation products including its innovative Quill™ Knotless Tissue-Closure Device, which is a bidirectional, barbed wound closure device. Today, Angiotech has several specialized direct sales and distribution organizations in the United States and the European Union, as well as significant manufacturing capabilities.

        Sentiment: Strong Buy

4.04-0.09(-2.18%)Oct 26 4:00 PMEDT